Key Opinion Leader Event
Nov 8, 2021
10:30 AM EST
Galecto will host a key opinion leader event to discuss the current treatment landscape for NSCLC, as well as the potential for GB1211, Galecto’s galectin-3 inhibitor that is expected to enter a phase 2 trial in 1H 2022.